Lundbeck is co-founding a new private-public partnership to enhance the quantity and quality of clinical research in dementia diseases, e.g. Alzheimer’s disease, in Denmark. In the new NEXT-Link Dementia network, Lundbeck joins specialized dementia clinics from five Danish hospitals to improve the conditions for running clinical trials.
The network is part of NEXT – National Experimental Therapy Partnership – which works to optimize all processes from start-up to close out of clinical trials with the optimization of legal and regulatory processes highly prioritized. The ambition is to make Denmark the pharmaceutical industry’s first choice for early clinical trials of new drugs for patients with particular focus on Proof of Concept-trials.
“We are pleased to participate in this new network which will hopefully prove a boost to the whole field of clinical dementia research in Denmark to the benefit of patients, society and companies like Lundbeck. Optimized processes around clinical trials in Denmark makes it more attractive for us to include Danish sites when we run trials for our Alzheimer’s and potentially also Parkinson’s programs”, says Mads Dalsgaard, Senior Vice President, Clinical Development.